References
- Knopman D S, DeKosky S T, Cummings J L, et al. Practice parameter: diagnosis of dementia (an evidence-based review) – report of the quality standards subcommittee of the American academy of neurology. Neurology 2001; 56: 1143–1153
- Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity. Journal of Neural Transmission 2004; 111: 247–272
- Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurology 2003; 2: 605–613
- Sunderland T, Linker G, Mirza N, et al. Decreased β-amyloid 1– 42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer’s disease. Journal of the American Medical Association 2003; 289: 2094–2103
- Wiltfang J, Lewczuk P, Riedere P, et al. Consensus paper of the WFSBP task force on biological markers of dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World Journal of Biological Psychiatry 2005; 6: 69–84
- Zetterberg H, Wahlund L O, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neuroscience Letters 2003; 352: 67–69
- Zanusso G, Fiorini M, Farinazzo A, et al. Phosporylated 14-3-3ζ protein in the CSF of neuroleptic-treated patients. Neurology 2005; 64: 1618–1620